Business
LENZ Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Highlights
Launched VIZZ® (aceclidine ophthalmic solution) 1.44% for the treatment of presbyopia in October 2025 and generated net product revenues of $1.6 million in
About this update from Lenz Therapeutics, Inc.
[{"type":"text","content":"Launched VIZZ® (aceclidine ophthalmic solution) 1.44% for the treatment of presbyopia in October 2025 and generated net product revenues of $1.6 million in the first quarter of launch On pace for over 45,000 paid prescriptions filled from launch through Q1 2026, written by more than 10,000 prescribing eye care professionals Compelling real-world performance of VIZZ, combined with broad prescriber uptake and encouraging early refill trends, reinforces confidence in its best-in-class profile and establishment of a durable new category Management to host conference call today, March 24, 2026, at 8:30am EDT SAN DIEGO, March 24, 2026 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (Nasdaq: LENZ or “LENZ” or the “Company”), a pharmaceutical company focused on the commercialization of VIZZ® (aceclidine ophthalmic solution) 1.44%, the first and only aceclidine-based eye drop for the treatment of presbyopia, today reported financial results for the fourth quarter and full year ended December 31, 2025 and recent corporate highlights. “We are encouraged by the early performance of VIZZ. We undoubtedly have a product that works, with broad prescriber uptake and early signs of encouraging refill dynamics reinforcing its best-in-class profile,” said Eef Schimmelpennink, President and Chief Executive Officer of LENZ Therapeutics. “We are clearly establishing a new category, with physicians building new habits of identifying appropriate patients and incorporating VIZZ into routine discussions. To accelerate this, we are leaning in by expanding our sales force, driving focused field execution and sharpening our physician messaging, as well as activating targeted consumer campaigns to establish VIZZ as a compelling alternative to reading glasses that is effective for the majority of presbyopes.” Fourth Quarter 2025 and Recent Corporate Highlights Commercial Launch First commercial product sale of VIZZ in October 2025, the first and only aceclidine-based eye drop for the treatment of presbyopiaQ4 2025 product revenue of approximately $1.6 million, driven by over 20,000 filled prescriptionsOn pace for over 45,000 paid prescriptions from launch through Q1 2026 Strong Prescriber Adoption Broad uptake by eye care professionals (“ECPs”), with over 6,500 unique prescribers in Q4 2025, on pace to grow to over 10,000 through Q1 2026.Notably, over 55% of presc...